» Articles » PMID: 35730384

Long-lasting Adaptive Immune Memory Specific to SARS-CoV-2 in Convalescent Coronavirus Disease 2019 Stable People with HIV

Abstract

Objective: While the course of natural immunization specific to SARS-CoV-2 has been described among convalescent coronavirus disease 2019 (COVID-19) people without HIV (PWOH), a thorough evaluation of long-term serological and functional T- and B-cell immune memory among people with HIV (PWH) has not been reported.

Methods: Eleven stable PWH developing mild ( n  = 5) and severe ( n  = 6) COVID-19 and 39 matched PWOH individuals with mild (MILD) ( n  = 20) and severe (SEV) ( n  = 19) COVID-19 infection were assessed and compared at 3 and 6 months after infection for SARS-CoV-2-specific serology, polyfunctional cytokine (interferon-γ [IFN-γ], interleukin 2 [IL-2], IFN-γ/IL-2, IL-21) producing T-cell frequencies against four main immunogenic antigens and for circulating SARS-CoV-2-specific immunoglobulin G (IgG)-producing memory B-cell (mBc).

Results: In all time points, all SARS-COV-2-specific adaptive immune responses were highly driven by the clinical severity of COVID-19 infection, irrespective of HIV disease. Notably, while a higher proportion of mild PWH showed a higher decay on serological detection between the two time points as compared to PWOH, persistently detectable IgG-producing mBc were still detectable in most patients (4/4 (100%) for SEV PWH, 4/5 (80%) for MILD PWH, 10/13 (76.92%) for SEV PWOH and 15/18 (83.33%) for MILD PWOH). Likewise, SARS-CoV-2-specific IFN-γ-producing T-cell frequencies were detected in both PWH and PWOH, although significantly more pronounced among severe COVID-19 (6/6 (100%) for SEV PWH, 3/5 (60%) for MILD PWH, 18/19 (94.74%) for SEV PWOH and 14/19 (73.68%) for MILD PWOH).

Conclusions: PWH develop a comparable short and long-term natural functional cellular and humoral immune response than PWOH convalescent patients, which are highly influenced by the clinical severity of the COVID-19 infection.

Citing Articles

Vaccine responses and hybrid immunity in people living with HIV after SARS-CoV-2 breakthrough infections.

Alirezaylavasani A, Skeie L, Egner I, Chopra A, Dahl T, Prebensen C NPJ Vaccines. 2024; 9(1):185.

PMID: 39384763 PMC: 11464709. DOI: 10.1038/s41541-024-00972-3.


Long COVID among people with HIV: A systematic review and meta-analysis.

Yang X, Shi F, Zhang H, Giang W, Kaur A, Chen H HIV Med. 2024; 26(1):6-16.

PMID: 39252604 PMC: 11725417. DOI: 10.1111/hiv.13708.


Viruses in Wastewater-A Concern for Public Health and the Environment.

Bleotu C, Matei L, Dragu L, Necula L, Pitica I, Chivu-Economescu M Microorganisms. 2024; 12(7).

PMID: 39065197 PMC: 11278728. DOI: 10.3390/microorganisms12071430.


SARS-CoV-2 Humoral and Cellular Immune Responses in People Living with HIV.

Ruta S, Popescu C, Matei L, Grancea C, Paun A, Oprea C Vaccines (Basel). 2024; 12(6).

PMID: 38932392 PMC: 11209143. DOI: 10.3390/vaccines12060663.


Serum SARS-CoV-2 antibodies in HIV-1-infected patients after inactivated vaccination and SARS-CoV-2 infection.

Zhang X, Han D, Wu N Heliyon. 2024; 10(11):e31731.

PMID: 38828333 PMC: 11140786. DOI: 10.1016/j.heliyon.2024.e31731.